88 related articles for article (PubMed ID: 7780886)
21. [Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study].
Cao KJ; Zhang AL; Ma WJ; Huang PY; Luo DH; Xia WX
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):50-2. PubMed ID: 21575465
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
Yeh KH; Cheng AL; Lin MT; Hong RL; Hsu CH; Lin JF; Chang KJ; Lee PH; Chen YC
Anticancer Res; 1997; 17(5B):3867-71. PubMed ID: 9427794
[TBL] [Abstract][Full Text] [Related]
23. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Czito BG; Hong TJ; Cohen DP; Tyler DS; Lee CG; Anscher MS; Ludwig KA; Seigler HF; Mantyh C; Morse MA; Lockhart AC; Petros WP; Honeycutt W; Spector NL; Ertel PJ; Mangum SG; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):779-85. PubMed ID: 14967434
[TBL] [Abstract][Full Text] [Related]
24. [Cardiotoxicity of 5-fluorouracil].
Pan L; Yang X; Song H
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):86-9. PubMed ID: 8758800
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity of 5-fluorouracil.
Collins C; Weiden PL
Cancer Treat Rep; 1987; 71(7-8):733-6. PubMed ID: 3300968
[TBL] [Abstract][Full Text] [Related]
26. Electrocardiographic manifestations of 5-fluorouracil cardiotoxicity.
Vivas Y; Chrissoheris M
Conn Med; 2005 Aug; 69(7):405-6. PubMed ID: 16350484
[No Abstract] [Full Text] [Related]
27. Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma.
Vogel SJ; Presant CA; Ratkin GA; Klahr C
Cancer Treat Rep; 1979 Jan; 63(1):1-5. PubMed ID: 369680
[TBL] [Abstract][Full Text] [Related]
28. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
Shaib W; Lee V; Saif MW
In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
[TBL] [Abstract][Full Text] [Related]
29. 5-fluorouracil-Induced cardiotoxicity.
Shanmugasundaram S; Bharathithasan R; Elangovan S
Indian Heart J; 2002; 54(1):86-7. PubMed ID: 11999096
[TBL] [Abstract][Full Text] [Related]
30. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
[TBL] [Abstract][Full Text] [Related]
32. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
33. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
34. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
Meydan N; Kundak I; Yavuzsen T; Oztop I; Barutca S; Yilmaz U; Alakavuklar MN
Jpn J Clin Oncol; 2005 May; 35(5):265-70. PubMed ID: 15855175
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease.
Tsibiribi P; Descotes J; Lombard-Bohas C; Barel C; Bui-Xuan B; Belkhiria M; Tabib A; Timour Q
Bull Cancer; 2006 Mar; 93(3):E27-30. PubMed ID: 16567310
[TBL] [Abstract][Full Text] [Related]
37. ["Iatrogenic acute coronary syndrome"--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].
Gundling F; Fuchs M; Nowak L; Antoni D; Hoffmann E; Schepp W
Z Gastroenterol; 2006 Sep; 44(9):975-9. PubMed ID: 16981070
[TBL] [Abstract][Full Text] [Related]
38. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
39. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
40. ST-Segment Elevation Myocardial Infarction Caused by 5-Fluorouracil-Related Cardiotoxicity.
Balaji N; Dixit P; Adams AM; Faiz F; Ngwainmbi D; Henry G; Ghasemzadeh N
Cureus; 2024 Jan; 16(1):e52864. PubMed ID: 38406077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
